Anti-human IL-21 monoclonal antibodies
US7883700B2 · kind B2 · utility
3Cited by
6References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 8, 2008 |
| Grant date | Feb 8, 2011 |
| Priority date | — |
| Expiry date | Dec 8, 2028 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.